Latest News

$5 million raise to accelerate global market development and product development AUCKLAND, New Zealand, December 05, 2022— Pictor, a global leader in immunodiagnostics, today announced a funding round to help accelerate pipeline product development projects along with market development activities within Australia/New Zealand, the US and Europe for its Human Health and Animal Health portfolios. This […]

November 16, 2022 12pm NZDT AUCKLAND, New Zealand — Pictor, a global leader in immunodiagnostics, today announced that its PictArray™ SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) antibody test will soon be available in New Zealand. Rako Science will utilize its national network by collecting blood samples with a device from Tasso, Inc., and undertake testing […]

Following a new investment of $6.1 million (NZD $8.8 million), biotech company Pictor today announced a partnership with U.S. laboratory service provider Mobility Health, launching a new antibody test as an important advance in COVID-19 monitoring and treatment. The investment, led by former Morrison & Co CEO Marko Bogoievski, and specialist growth investor K One W One Ltd. (K1W1), will support market and product development of the new antibody test and other Pictor in vitro diagnostics.

New Zealand diagnostic biotech company Pictor Ltd. announced today that it has successfully completed validation trials at two separate sites in the United States, one of which was Florida-based Boca Biolistics, for its COVID-19 antibody test. “We were delighted with the performance observed in the Alpha studies which gave us confidence to rapidly proceed with trials in the USA,” said Pictor Chief Technology Officer Dr. Richard Janeczko. “We feel the duplex nature of our test is a unique feature which provides much better data interpretation from serology testing for use the ongoing management of the global pandemic.” The company now aims to fast-track adoption of its low-cost, high-performance, high-throughput tests by obtaining FDA Emergency Use Authorization.